1. Ortel, T.L. et al. (2020) ‘American Society of Hematology 2020 Guidelines for management of venous thromboembolism: Treatment of deep vein thrombosis and pulmonary embolism’, Blood Advances, 4(19), pp. 4693–4738. doi:10.1182/bloodadvances.2020001830.
2. Fonte: Ministério da Saúde - Sistema de Informações Hospitalares do SUS (SIH/SUS)
3. Síntese de evidências para políticas de saúde: congestão e superlotação dos serviços hospitalares de urgências [recurso eletrônico] / Ministério da Saúde. Secretaria de Ciência, Tecnologia, Inovação e Insumos Estratégicos em Saúde. Departamento de Ciência e Tecnologia. – Brasília : Ministério da Saúde, 2020. 81 p.: il.
4. Sprivulis, P.C. et al. (2006) ‘The association between hospital overcrowding and mortality among patients admitted via Western Australian Emergency Departments’, Medical Journal of Australia, 184(12), pp. 616–616. doi:10.5694/j.1326-5377.2006.tb00416.x.
5. Vandy FC, Stabler C, Eliassen AM et al. Soluble P-selectin for the diagnosis of lower extremity deep venous thrombosis. J Vasc Surg Venous Lymph Disord. 2013;1(2): 117-25.
6. Green, D. (2002) ‘Pitfalls in the use of anticoagulants’, Hemodialysis International, 6(1), pp. 47–53. doi:10.1111/hdi.2002.6.1.47.
7. Wallace S, Clark M, White J. ‘It’s on my iPhone’: attitudes to the use of mobile computing devices in medical education, a mixed methods study. BMJ Open 2012 Aug;2;e001099.
8. C. Lee Ventola, MS, Mobile Devices and Apps for Healthcare professionals: Uses and Benefits , P&T May 2014 • Vol. 39 No. 5
9. Evidence of effectiveness of health care professionals using handheld computers: a scoping review of systematic reviews Sharon Mickan 1, Julie K Tilson, Helen Atherton, Nia Wyn Roberts, Carl Heneghan
10. The use of personal digital assistants in clinical decision making by health care professionals: a systematic review Pip Divall 1, Janette Camosso-Stefinovic, Richard Baker
11. Mobile Devices and Apps for Health Care Professionals: Uses and Benefits C. Lee Ventola, MS
12. Wells PS, Hirsh J, Anderson DR, et al. Accuracy of clinical assessment of deep-vein thrombosis. Lancet 1995; 345:1326.
13. Wells PS, Anderson DR, Bormanis J, et al. Value of assessment of pretest probability of deep-vein thrombosis in clinical management. Lancet 1997; 350:1795.
14. Kafeza M, Shalhoub J, Salooja N et al. A systematic review of clinical prediction scores for deep vein thrombosis. Phlebology. 2017;32(8): 516-31.
15. Stein PD, Terrin ML, Hales CA, et al. Clinical, laboratory, roentgenographic, and electrocardiographic findings in patients with acute pulmonary embolism and no pre-existing cardiac or pulmonary disease. Chest 1991; 100:598.
16. Lucassen W, Geersing GJ, Erkens PM, et al. Clinical decision rules for excluding pulmonary embolism: a meta-analysis. Ann Intern Med 2011; 155:448.
17. van Belle A, Büller HR, Huisman MV, et al. Effectiveness of managing suspected pulmonary embolism using an algorithm combining clinical probability, D-dimer testing, and computed tomography. JAMA 2006; 295:172.
18. Albricker, A.C. et al. (2022) ‘Diretriz conjunta sobre tromboembolismo venoso – 2022’, Arquivos Brasileiros de Cardiologia, 118(4), pp. 805–807. doi:10.36660/abc.20220213.
19. Darwish Murad S, Valla DC, de Groen PC, et al. Determinants of survival and the effect of portosystemic shunting in patients with Budd‐Chiari syndrome. Hepatology (Baltimore, MD). 2004;39(2):500‐508.
20. Venous thrombosis in unusual sites: A practical review for the hematologist Venous thrombosis in unusual sites: A practical review for the hematologist p5
21. Zeitoun G, Escolano S, Hadengue A, et al. Outcome of Budd‐Chiari syndrome: a multivariate analysis of factors related to survival including surgical portosystemic shunting. Hepatology (Baltimore, MD). 1999;30(1):84‐89.
22. Ageno W, Riva N, Schulman S, et al. Long‐term clinical outcomes of splanchnic vein thrombosis: results of an international registry. JAMA Intern Med. 2015;175(9):1474‐1480.
23. Venous thrombosis in unusual sites: A practical review for the hematologist Venous thrombosis in unusual sites: A practical review for the hematologist p5, 7
24. Heider TR, Azeem S, Galanko JA, Behrns KE. The natural history of pancreatitis‐induced splenic vein thrombosis. Ann Surg. 2004;239(6):876‐882.
25. Loftus JP, Nagorney DM, Ilstrup D, Kunselman AR. Sinistral portal hypertension. Splenectomy or expectant management. Ann Surg. 1993;217(1):35‐40.
26. Kumar S, Sarr MG, Kamath PS. Mesenteric venous thrombosis. N
27. Acosta S, Alhadad A, Svensson P, Ekberg O. Epidemiology, risk and prognostic factors in mesenteric venous thrombosis. Br J Surg. 2008;95(10):1245‐1251
28. Amitrano L, Brancaccio V, Guardascione MA, et al. High prevalence of thrombophilic genotypes in patients with acute mesenteric vein thrombosis. Am J Gastroenterol. 2001;96(1):146‐149
29. Sutkowska E, McBane RD, Tafur AJ, et al. Thrombophilia differences in splanchnic vein thrombosis and lower extremity deep venous thrombosis in North America. J Gastroenterol. 2013;48(10):1111‐1118.
30. Kumar, S., Sarr, M.G. and Kamath, P.S. (2001) ‘Mesenteric venous thrombosis’, New England Journal of Medicine, 345(23), pp. 1683–1688. doi:10.1056/nejmra010076.
31. Saposnik G, Barinagarrementeria F, Brown RD, et al. Diagnosis and management of cerebral venous thrombosis: a statement for healthcare professionals from the American Heart Association/ American Stroke Association. Stroke 2011;42:1158–92.
32. Canhao P, Ferro JM, Lindgren AG, et al. Causes and predictors of death in cerebral venous thrombosis. Stroke 2005;36:1720–5.
33. Avanali R, Gopalakrishnan MS, Devi BI, et al. Role of decompressive craniectomy in the management of cerebral venous sinus thrombosis. Front Neurol 2019;10:511.
34. Ulivi, L. et al. (2020) ‘Cerebral venous thrombosis: A practical guide’, Practical Neurology, 20(5), pp. 356–367. doi:10.1136/practneurol-2019-002415.
35. Gulati D, Strbian D, Sundararajan S. Cerebral venous thrombosis: diagnosis and management. Stroke 2014;45:e16–8.
36. Lobo S, Ferro JM, Barinagarrementeria F, et al. Shunting in acute cerebral venous thrombosis: a systematic review. Cerebrovasc Dis 2014;37:38–42.
37. Ferro JM, Canhao P, Stam J, et al. Prognosis of cerebral vein and dural sinus thrombosis: results of the International Study on Cerebral Vein and Dural Sinus Thrombosis (ISCVT). Stroke 2004;35:664–70.
38. Ageno W, Beyer-Westendorf J, Garcia DA, Lazo-Langner A, McBane RD, Paciaroni M. Guidance for the management of venous thrombosis in unusual sites. J Thromb Thrombolysis. 2016;41(1):129-14
39. Alons IME, Jellema K, Wermer MJH, et al. D-dimer for the exclusion of cerebral venous thrombosis: a meta-analysis of low risk patients with isolated headache. BMC Neurol 2015;15:118
40. Rehak M, Wiedemann P. Retinal vein thrombosis: pathogenesis and management. J Thromb Haemost. 2010;8(9):1886‐1894.
41. Rogers S, McIntosh RL, Cheung N, et al. The prevalence of retinal vein occlusion: pooled data from population studies from the United States, Europe, Asia, and Australia. Ophthalmology. 2010;117(2):313‐319.e311.
42. Newman‐Casey PA, Stem M, Talwar N, Musch DC, Besirli CG, Stein JD. Risk factors associated with developing branch retinal vein occlusion among enrollees in a United States managed care plan. Ophthalmology. 2014;121(10):1939‐1948.
43. Yannuzzi LA, Sorenson JA, Sobel RS, et al. Risk factors for central retinal vein occlusion. The Eye Disease Case‐Control Study Group. Arch Ophthalmol. 1996;114(5):545‐554.
44. McAllister IL. Central retinal vein occlusion: a review. Clin Exp Ophthalmol. 2012;40(1):48‐58.
45. Squizzato A, Manfredi E, Bozzato S, Dentali F, Ageno W. Antithrombotic and fibrinolytic drugs for retinal vein occlusion: a systematic review and a call for action. Thromb Haemost. 2010;103(2):271‐276.
46. Mruthyunjaya P, Wirostko WJ, Chandrashekhar R, et al. Central retinal vein occlusion in patients treated with long‐term warfarin sodium (Coumadin) for anticoagulation. Retina. 2006;26(3):285‐291.
47. Cote LP, Greenberg S, Caprini JA, et al. Comparisons between upper and lower extremity deep vein thrombosis: a review of the RIETE registry. Clin Appl Thromb. 2017. DOI:10.1177/1076029616663847.
48. Khan, O., Marmaro, A. and Cohen, D.A. (2021) ‘A review of upper extremity deep vein thrombosis’, Postgraduate Medicine, 133(sup1), pp. 3–10. doi:10.1080/00325481.2021.1892390.
49. Mazzolai L, Aboyans V, Ageno W, et al. Diagnosis and management of acute deep vein thrombosis: a joint consensus document from the European Society of Cardiology working groups of aorta and peripheral vascular diseases and pulmonary circulation and right ventricular function. Eur Heart J. 2018. DOI:10.1093/eurheartj/ehx003.
50. Kearon C, Akl EA, Comerota AJ, et al. Antithrombotic therapy for VTE disease. Chest. 2012. DOI:10.1378/chest.11-2301.
51. Zwicker JI, Connolly G, Carrier M, et al. Catheter-associated deep vein thrombosis of the upper extremity in cancer patients: gui­dance from the SSC of the ISTH. J Thromb Haemost. 2014;12:5.
52. Streiff MB, Holmstrom B, Angelini D, et al. NCCN Guidelines® insights cancer-associated venous thromboembolic disease, version 2.2018 featured updates to the NCCN guidelines. JNCCN J Natl Compr Cancer Netw. 2018;16:11.
53. Wysokinski WE, Gosk‐Bierska I, Greene EL, Grill D, Wiste H, McBane RD 2nd. Clinical characteristics and long‐term follow‐up of patients with renal vein thrombosis. Am J Kidney Dis. 2008;51(2):224‐232.
54. Llach F, Papper S, Massry SG. The clinical spectrum of renal vein thrombosis: acute and chronic. Am J Med. 1980;69(6):819‐827.
55. Singhal R, Brimble KS. Thromboembolic complications in the nephrotic syndrome: pathophysiology and clinical management. Thromb Res. 2006;118(3):397‐407.
56. Kanfer A. Coagulation factors in nephrotic syndrome. Am J Nephrol. 1990;10(Suppl 1):63‐68.
57. Rabelink TJ, Zwaginga JJ, Koomans HA, Sixma JJ. Thrombosis and hemostasis in renal disease. Kidney Int. 1994;46(2):287‐296.
58. Ribic, C. and Crowther, M. (2016) ‘Thrombosis and anticoagulation in the setting of renal or liver disease’, Hematology, 2016(1), pp. 188–195. doi:10.1182/asheducation-2016.1.188.
59. Cancer-associated thrombosis: enhanced awareness and pathophysiologic complexity
60. Challenges in managing patients on anticoagulation: Thrombocytopenia, resumption after bleeding and recurrent thrombosis
61. Oral Anticoagulant Use After Bariatric Surgery: A Literature Review and Clinical Guidance
62. Kushnir, M. et al. (2023) ‘Direct oral XA inhibitors for the treatment of venous thromboembolism after bariatric surgery’, Blood Advances, 7(2), pp. 224–226. doi:10.1182/bloodadvances.2021006696.
63. Schulman S, Kearon CSubcommittee on Control of Anticoagula- tion of the Scientific and Standardization Committee of the International Society on Thrombosis and Haemostasis. Definition of major bleeding in clinical investigations of antihemostatic medicinal products in non-surgical patients. J Thromb Haemost 2005;3(04):692–694
64. ISTH abstract - Inpatient THrombophilia testing
65. Thrombophilia testing: A British Society for Haematology guideline
66. Stevens, S.M. et al. (2016) ‘Guidance for the evaluation and treatment of hereditary and acquired thrombophilia’, Journal of Thrombosis and Thrombolysis, 41(1), pp. 154–164. doi:10.1007/s11239-015-1316-1.
67. Addendum to British Society for Haematology Guidelines on Investigation and Management of Antiphospholipid syndrome, 2012 (Br. J. Haematol. 2012; 157: 47–58): use of direct acting oral anticoagulants
68. CAT Categorization of patients as having provoked or unprovoked venous thromboembolism: guidance from the SSC of ISTH
69. Douketis, J.D., Spyropoulos, A.C., Murad, M.H., Arcelus, J.I., Dager, W.E., Dunn, A.S., Fargo, R.A., Levy, J.H., Samama, C.M., Shah, S.H., Sherwood, M.W., Tafur, A.J., Tang, L.V. and Moores, L.K. (2022). Perioperative Management of Antithrombotic Therapy: An American College of Chest Physicians Clinical Practice Guideline. CHEST, [online] 0(0). doi:https://doi.org/10.1016/j.chest.2022.07.025.
70. Kearon, C., Akl, E.A., Ornelas, J., Blaivas, A., Jimenez, D., Bounameaux, H., Huisman, M., King, C.S., Morris, T.A., Sood, N., Stevens, S.M., Vintch, J.R.E., Wells, P., Woller, S.C. and Moores, L. (2016). Antithrombotic Therapy for VTE Disease. Chest, [online] 149(2), pp.315–352. doi:https://doi.org/10.1016/j.chest.2015.11.026.
71. Kearon, C., Akl, E.A., Comerota, A.J., Prandoni, P., Bounameaux, H., Goldhaber, S.Z., Nelson, M.E., Wells, P.S., Gould, M.K., Dentali, F., Crowther, M. and Kahn, S.R. (2012). Antithrombotic therapy for VTE disease: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest, [online] 141(2 Suppl), pp.e419Se496S. doi:https://doi.org/10.1378/chest.11-2301. ‌

Créditos: Este aplicativo foi desenvolvido como parte do Trabalho de Conclusão de Curso da Residência Médica de Hematologia e Hemoterapia de Giullio Savi e Mariana Spadoni, sob orientação da atual Presidente da Sociedade Brasileira de Trombose e Hemostasia, Profª. Drª. Joyce Maria Annichino-Bizzacchi. Foi elaborado com recursos próprios no Hemocentro de Campinas e contou com apoio do Centro de Doenças Tromboembólicas do Hemocentro - UNICAMP. A programação foi desenvolvida em conjunto pelo orientando e pelo programador Lucas Trentim Navarro de Almeida, o design gráfico, esquema de cores e logotipo do aplicativo foram desenvolvidos pelo designer gráfico Vinicius Laranjeira Trentin.